FDA Approves New Treatments for Cancer and Kidney Disease, Expands Use for Bladder Cancer Therapy

The U.S. Food and Drug Administration (FDA) has announced several significant drug approvals in early July 2026. These include the approval of atacicept-vymj (Trutakna) on July 7 for primary immunoglobulin A nephropathy, a serious kidney disease. On July 10, the FDA expanded the use of pembrolizumab (Keytruda) in combination with enfortumab vedotin-ejfv for adults with muscle-invasive bladder cancer. Additionally, on July 14, selpercatinib (Retevmo) received full approval for adults and children aged 2 years and older with locally advanced or metastatic solid tumors with a RET gene fusion, converting prior accelerated approvals. Also on July 14, gedatolisib (Revtorpyk) received its first regulatory approval for use in combination with hormone therapy and Pfizer's Ibrance for certain people with ER-positive, HER2-negative advanced breast cancer.

Context

The FDA plays a crucial role in regulating and approving new medications to ensure their safety and efficacy. Primary immunoglobulin A nephropathy and various cancers, including muscle-invasive bladder cancer and advanced breast cancer, affect thousands of patients in the U.S. The approvals reflect ongoing research and development in the pharmaceutical industry aimed at addressing unmet medical needs.

Why it matters

The FDA's recent approvals represent significant advancements in the treatment options for serious health conditions, including kidney disease and various cancers. These approvals can lead to improved patient outcomes and quality of life. With the expansion of existing therapies, more patients may have access to effective treatments that were previously limited.

Implications

Patients diagnosed with the specified conditions may experience improved treatment outcomes, potentially leading to better survival rates and quality of life. The approvals may also influence healthcare costs and insurance coverage for these therapies. Pharmaceutical companies may see increased interest in developing similar treatments, impacting future research funding and drug development.

What to watch

Healthcare providers will begin integrating these new treatment options into patient care protocols. Patient responses to these therapies will be closely monitored to assess their effectiveness and any potential side effects. Additionally, further studies may emerge to explore the long-term impacts of these treatments.